AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Business Wire•05/10/2026•07:00 ET
0
Key Highlights
- ➤AstraZeneca invests $2.0 billion in Summit Therapeutics equity
- ➤Investment converts at $18.36 per common share, a premium
- ➤Summit will accelerate ivonescimab development across multiple solid tumors
- ➤Ivonescimab has 16 announced, ongoing, or completed Phase III studies
- ➤FDA accepted Summit’s HARMONi BLA; goal PDUFA date is November 14, 2026
Expert Statements
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“This investment reflects AstraZeneca’s confidence in Summit and in ivonescimab’s potential to redefine cancer treatment”
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“We share a resolute vision for what may be possible for patients, and this strategic relationship strengthens our ability to pursue that vision with urgency, purpose, and an unwavering commitment to meaningfully improving outcomes.”
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody.
Get started
Create a free account to read the full story.